Therapeutic | Guselkumab |
Target | IL23A |
Heavy Chain | EVQLVQSGAEVKKPGESLKISCKGSGYSFSNYWIGWVRQMPGKGLEWMGIIDPSNSYTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARWYYKPFDVWGQGTLVTVSS |
Light Chain | QSVLTQPPSVSGAPGQRVTISCTGSSSNIGSGYDVHWYQQLPGTAPKLLIYGNSKRPSGVPDRFSGSKSGTSASLAITGLQSEDEADYYCASWTDGLSLVVFGGGTKLTVL |
100% seqID Fv Structure | 4m6m [Fvs: HL], 4m6n [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4m6m [Fvs: HL] |
100% seqID Structure | 4m6n [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | MorphoSys HuCAL Phage Display |
INN Year Proposed | 2013 |
INN Year Recommended | 2014 |
Companies Involved | Janssen Biotech, MorphoSys, Taiho Pharmaceutical |
Conditions Approved | Erythrodermic psoriasis, Palmoplantar pustulosis, Plaque psoriasis, Psoriatic arthritis, Pustular psoriasis |
Conditions Active | Crohn's disease, Hidradenitis suppurativa, Rheumatoid arthritis, Ulcerative colitis, Familial adenomatous polyposis |
Conditions Discontinued | na |
Notes |